Fecal Calprotectin Test Market Size & Growth Forecast 2027–2036, By Segments (Assay, Application, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Fecal Calprotectin Test Market size was around USD 6.2 billion in 2026 and is slated to grow at a 10.64% CAGR from 2027 to 2036, surpassing USD 17.04 billion by 2036. The industry revenue for 2027 is calculated at USD 6.76 billion.
Get more details on this report
Request Free Sample ReportFecal Calprotectin Test Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 48.97% share due to strong diagnostic infrastructure, widespread clinical use of noninvasive GI testing, and routine integration into hospital and laboratory workflows.
- Asia Pacific grows at 12.43% CAGR driven by improving lab access, rising GI disorder diagnosis, and increasing adoption of noninvasive biomarkers in routine gastroenterology practice.
Segment Momentum
- ELISA leads with 64.41% share due to strong clinical adoption, laboratory familiarity, and reliable integration into routine workflows for consistent intestinal inflammation biomarker testing.
- Colorectal cancer is the fastest-growing application as demand rises for non-invasive testing approaches that support early assessment, patient triage, and reduced reliance on invasive diagnostic procedures.
Market Expansion Drivers
- Rising prevalence of IBD and IBS increasing demand for non-invasive gastrointestinal diagnostics.
- Advancements in point-of-care diagnostic technologies improving accessibility and turnaround times.
- Growing adoption of home-based diagnostic kits expanding patient-centric gastrointestinal monitoring solutions.
Leading Market Participants
- Top players in the fecal calprotectin test market include Abbott Laboratories (USA), Thermo Fisher Scientific Inc. (USA), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux SA (France), BÜHLMANN Laboratories AG (Switzerland), DiaSorin S.p.A. (Italy), ALPCO Diagnostics (USA), Eagle Biosciences, Inc. (USA), Svar Life Science AB (Sweden), DRG International, Inc. (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.2 billion
- 2027 Estimated Market Size: USD 6.76 billion.
- Projected Market Size: USD 17.04 billion by 2036
- Growth Forecast: 10.64% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Enzyme-linked Immunosorbent Assay (Assay) | Inflammatory Bowel Disease (Application) | Hospitals and Clinics (End-use)
- Emerging Opportunity Segment: Enzyme Fluroimmunoassay (Assay) | Colorectal Cancer (Application) | Diagnostic Laboratories (End-use)
Market Growth Drivers and Industry Trends
Rising prevalence of IBD and IBS increasing demand for non-invasive gastrointestinal diagnostics
The growing burden of inflammatory bowel disease and irritable bowel syndrome is creating a stronger need for diagnostic approaches that can distinguish gastrointestinal inflammation from functional disorders, supporting fecal calprotectin test market growth. Fecal calprotectin testing provides a non-invasive method for assessing intestinal inflammation and can help clinicians determine whether further investigations such as endoscopic procedures may be appropriate. Its ability to support disease assessment without requiring invasive tissue sampling makes it useful in the diagnostic and monitoring pathways for patients experiencing persistent gastrointestinal symptoms. Increasing awareness of early disease identification and the need to manage recurrent symptoms are encouraging healthcare providers to incorporate stool-based inflammatory biomarkers into gastrointestinal diagnostic workflows.
Advancements in point-of-care diagnostic technologies improving accessibility and turnaround times
Technological improvements in rapid diagnostic platforms are making gastrointestinal biomarker testing more accessible, while faster processing capabilities will propel fecal calprotectin test market growth. Point-of-care systems can reduce dependence on centralized laboratory workflows and enable healthcare professionals to obtain clinically useful results closer to the patient, supporting quicker evaluation and treatment decisions. Improvements in assay design, portable analyzers, sample processing, and automated interpretation are also helping simplify testing procedures for healthcare facilities with varying laboratory capabilities. Shorter turnaround times can be particularly valuable when clinicians need to differentiate inflammatory gastrointestinal conditions from non-inflammatory causes of symptoms during routine consultations.
Growing adoption of home-based diagnostic kits expanding patient-centric gastrointestinal monitoring solutions
The increasing shift toward convenient, patient-centered healthcare is encouraging the use of diagnostic solutions that can be performed with minimal disruption to daily routines, strengthening fecal calprotectin test market demand. Home-based testing allows patients to collect stool samples outside conventional clinical settings and may support more convenient monitoring for individuals requiring repeated assessment of gastrointestinal inflammation. Such approaches can reduce the need for frequent facility visits while facilitating greater patient participation in disease management. Improved sample collection methods, user-friendly testing formats, and integration with remote healthcare services are helping extend gastrointestinal monitoring beyond traditional laboratory environments.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of IBD and IBS increasing demand for non-invasive gastrointestinal diagnostics | 2.10% | Moderate | North America, Europe | High | Near Term |
| Advancements in point-of-care diagnostic technologies improving accessibility and turnaround times | 1.80% | Moderate | Asia Pacific, North America | High | Mid Term |
| Growing adoption of home-based diagnostic kits expanding patient-centric gastrointestinal monitoring solutions | 1.50% | Moderate | Europe, Asia Pacific | Emerging | Long Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America dominated the fecal calprotectin test market with a 48.97% share in 2026, supported by advanced diagnostic infrastructure, high awareness of gastrointestinal disorders, and established clinical use of noninvasive testing methods. Growing emphasis on early and accurate differentiation of inflammatory bowel conditions is encouraging the adoption of fecal biomarkers in clinical practice. Strong healthcare systems, access to specialized diagnostic services, and continued improvements in laboratory testing capabilities further reinforce the region's leading position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, driven by improving diagnostic infrastructure, rising awareness of gastrointestinal diseases, and expanding access to specialized healthcare services. Greater recognition of the value of noninvasive diagnostic approaches is encouraging healthcare providers to incorporate biomarker-based testing into disease evaluation and monitoring. Increasing healthcare investment, modernization of laboratory facilities, and broader adoption of advanced diagnostic technologies are creating favorable conditions for wider use of fecal calprotectin testing across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants/Startups i Scale Low Medium High | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Testing PrecisionGermany emphasizes high-quality fecal calprotectin testing supported by standardized laboratory workflows and reliable diagnostic performance. Clinical laboratories in Germany prioritize consistent analytical accuracy to strengthen gastrointestinal disease assessment and patient management.
France 🇫🇷
Gastrointestinal Care SupportFrance integrates fecal calprotectin testing into routine gastrointestinal diagnostics to assist with patient assessment and ongoing disease monitoring. Healthcare professionals in France prioritize validated testing methods that support efficient clinical decision-making and optimized patient management.
Italy 🇮🇹
Clinical Monitoring SolutionsItaly strengthens the use of fecal calprotectin testing in gastroenterology by supporting non-invasive monitoring of inflammatory bowel disorders. Laboratories and healthcare providers in Italy emphasize dependable assay performance and efficient integration into routine diagnostic workflows.
Japan 🇯🇵
Early Disease AssessmentJapan incorporates fecal calprotectin testing into gastroenterology practice to improve evaluation of intestinal inflammation and treatment monitoring. Healthcare providers in Japan focus on dependable diagnostic methods that enhance clinical efficiency and patient care pathways.
South Korea 🇰🇷
Diagnostic Workflow EfficiencySouth Korea continues expanding fecal calprotectin testing as healthcare providers seek faster, evidence-based approaches to gastrointestinal disease evaluation. Clinical laboratories in South Korea emphasize automated testing platforms that improve turnaround time and diagnostic consistency.
United States 🇺🇸
Non-Invasive DiagnosticsThe U.S. increasingly adopts fecal calprotectin testing to support early assessment and monitoring of inflammatory bowel conditions. Healthcare providers in the U.S. value accurate, non-invasive diagnostic tools that help reduce unnecessary invasive procedures and improve clinical decision-making.
Segment Leadership and Growth Trends
Fecal Calprotectin Test Market Share (%), by Assay, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportAssay Segment Analysis: Enzyme-linked Immunosorbent Assay (Largest Segment) vs Enzyme Fluroimmunoassay (Fastest-Growing Segment)
Enzyme-linked immunosorbent assay dominated the fecal calprotectin test market, accounting for a 64.41% share in 2026, supported by its established role in detecting and quantifying fecal calprotectin for the assessment of intestinal inflammation. The assay is widely suited to laboratory-based testing workflows and provides a practical approach for evaluating patients with suspected inflammatory gastrointestinal conditions. Its established clinical use, compatibility with laboratory procedures, and relevance to non-invasive assessment of intestinal inflammation contribute to its strong position within fecal calprotectin testing.
Enzyme fluroimmunoassay is gaining traction as diagnostic laboratories and healthcare providers seek testing approaches that can support efficient and sensitive biomarker assessment. Advances in immunoassay techniques and increasing emphasis on streamlined diagnostic workflows can encourage adoption of fluorescence-based testing approaches where appropriate. Growing demand for non-invasive gastrointestinal assessment, improved diagnostic efficiency, and broader utilization of biomarker testing is supporting the expansion of this assay segment.
Application Segment Analysis: Inflammatory Bowel Disease (Largest Segment) vs Colorectal Cancer (Fastest-Growing Segment)
The inflammatory bowel disease segment represented the largest application area in the fecal calprotectin test market, holding a 64.02% share in 2026. Fecal calprotectin testing is particularly valuable in inflammatory bowel disease management because it provides a non-invasive indication of intestinal inflammation and can support clinical assessment alongside other diagnostic methods. Its role in distinguishing inflammatory activity from conditions with similar gastrointestinal symptoms, as well as its usefulness in ongoing disease monitoring, supports continued demand for fecal calprotectin testing in this application.
Colorectal cancer is emerging as a faster-growing application as healthcare systems place greater emphasis on earlier detection, risk assessment, and non-invasive approaches to gastrointestinal evaluation. Fecal biomarkers can contribute to broader diagnostic pathways by providing information that may help determine the need for further clinical investigation. Increasing awareness of gastrointestinal disease, demand for less invasive testing approaches, and expanding interest in biomarker-based diagnostic strategies are supporting greater attention to fecal calprotectin testing in colorectal cancer-related applications.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Assay | Enzyme-linked Immunosorbent Assay, Enzyme Fluroimmunoassay, Quantitative Immunochromatography | Enzyme-linked Immunosorbent Assay | Enzyme Fluroimmunoassay |
| Application | Inflammatory Bowel Disease, Colorectal Cancer, Others | Inflammatory Bowel Disease | Colorectal Cancer |
| End-use | Hospitals and Clinics, Diagnostic Laboratories, Academic and Research Institutes | Hospitals and Clinics | Diagnostic Laboratories |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Major players in the fecal calprotectin test market:
1. Abbott Laboratories (USA)
2. Thermo Fisher Scientific Inc. (USA)
3. F. Hoffmann-La Roche Ltd (Switzerland)
4. bioMérieux SA (France)
5. BÃœHLMANN Laboratories AG (Switzerland)
6. DiaSorin S.p.A. (Italy)
7. ALPCO Diagnostics (USA)
8. Eagle Biosciences Inc. (USA)
9. Svar Life Science AB (Sweden)
10. DRG International Inc. (USA)
The fecal calprotectin test market is expanding as healthcare providers increasingly adopt non-invasive diagnostic methods for gastrointestinal disease assessment. Diagnostic developers are focusing on improving test sensitivity, automation compatibility, and result turnaround times to support faster clinical decision-making. Technological enhancements in biomarker detection and laboratory workflow integration are also contributing to greater adoption across healthcare facilities.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (USA) | |||||||
| Thermo Fisher Scientific Inc. (USA) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| bioMérieux SA (France) | |||||||
| BÜHLMANN Laboratories AG (Switzerland) | |||||||
| DiaSorin S.p.A. (Italy) | |||||||
| ALPCO Diagnostics (USA) | |||||||
| Eagle Biosciences Inc. (USA) | |||||||
| Svar Life Science AB (Sweden) | |||||||
| DRG International Inc. (USA). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Various Manufacturers | Jan-26 | Research presented at the 2026 Crohn’s & Colitis Congress highlighted critical assay variability in FDA-cleared fecal calprotectin tests. Findings indicated significant discrepancies in reference ranges and specificity across methodologies, suggesting that inconsistent performance may contribute to false positives and unnecessary follow-up colonoscopies, highlighting the need for improved standardization in diagnostic sensitivity and clinical application. |
| Eiken Chemical | 2026 | Eiken Chemical continues to expand the global adoption of the OC-SENSOR Ceres™ analyzer, which integrates fecal immunochemical testing (FIT) and calprotectin measurement on a single platform. This combined testing capability streamlines clinical workflows by allowing patients to use a single collection bottle for both assays, reducing laboratory processing steps and improving diagnostic turnaround times for IBD screening. |
| Various Payers | 2025 | Reflecting the clinical utility of calprotectin as a non-invasive biomarker, major health plans updated their medical policies throughout 2025 and early 2026 to formalize coverage for fecal calprotectin testing. These policies standardize the use of the test for the differential diagnosis of IBD versus IBS and for ongoing monitoring of disease activity, confirming its role as a surrogate marker for endoscopic remission. |
| Biohit | 2025 | Biohit continues to emphasize the clinical value of its quantitative calprotectin assays as an essential component of its digestive health diagnostic toolkit. The company focuses on the diagnostic utility of the test in differentiating inflammatory conditions from functional bowel disorders, actively supporting the shift toward non-invasive biomarkers to reduce the burden of unnecessary diagnostic investigations. |
| DiaSorin | 2022 | DiaSorin leverages the LIAISON® Calprotectin assay, a chemiluminescent-based test that remains a key component of its non-invasive IBD screening portfolio. The platform's capability to integrate with automated sample preparation devices, such as the LIAISON Q.S.E.T. Device Plus, continues to support laboratory efficiency by standardizing the pre-analytical phase of fecal sample handling. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Fecal Calprotectin Test Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Test Format | Laboratory-Based Tests, Point-of-Care Tests, At-Home & Near-Patient Tests |
| Automation Level | Manual Testing, Semi-Automated Testing, Fully Automated Testing |
| Purchasing Channel | Direct Institutional Procurement, Diagnostic Laboratory Networks & Group Purchasing, Distributors & Specialty Suppliers |
Fecal Calprotectin Test Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Diagnostic Adoption Roadmap |
|
| Reimbursement and Access Strategy |
|
| Clinical Workflow Integration Assessment |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of fecal calprotectin test?
What is the forecasted size of the fecal calprotectin test industry?
How is the rising prevalence of gastrointestinal disorders influencing diagnostic strategies in the fecal calprotectin test market?
How are point-of-care and home-based testing trends changing patient monitoring in the fecal calprotectin test market?
Why does ELISA dominate the fecal calprotectin test market?
What is driving growth in colorectal cancer applications?
Why is North America the leading region in this market?
What is driving growth in Asia Pacific fecal calprotectin testing?
Which companies dominate the fecal calprotectin test landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization